S11 Ep8: Salgia Summarizes the Benefits of Tepotinib in MET Exon 14–Mutated NSCLC

from OncLive® On Air · host OncLive® On Air

Dr Salgia discusses how he chooses between tepotinib and capmatinib in patients with stage IV NSCLC harboring MET exon 14 skipping mutations.

Episode metadata supplied by the publisher feed · Published Sep 2, 2024

Embed this episode

Attribution link and audio player

NOW PLAYING

S11 Ep8: Salgia Summarizes the Benefits of Tepotinib in MET Exon 14–Mutated NSCLC

0:00 12:55

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Similar Episodes

No similar episodes found.

No similar podcasts found.

This episode is 12 minutes long.

This episode was published on September 2, 2024.

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!